New Data for TecartusTM Demonstrate Durable Responses at One Year Follow-Up in Relapsed or Refractory Mantle Cell Lymphoma

Kite, a Gilead Company, today announced follow-up results from the pivotal ZUMA-2 trial of Tecartus™ in adult patients with relapsed or refractory mantle cell lymphoma. At a median follow-up of 17.5 months,